Atogepant open label data support long term efficacy and safety Sustained response to eptinezumab over 18 months Fresh insights on CGRP mAb and gepant prescribing New data support central action for fremanezumab and ubrogepant Zavegepant reduces need for analgesics AHS recommends anti-CGRP therapies as first line for migraine prevention Imaging data support central effects of erenumab Additive effects of multiple anti-CGRP therapies seen on CGRP-induced vasorelaxation

Erenumab

Erenumab

In May 2018, Aimovig (erenumab) became the first CGRP monoclonal antibody to be approved for the prevention of migraine in adults. Approval was supported by data including results of the Phase 3 STRIVE and ARISE studies in episodic migraine and the results of a large Phase 2 study in chronic migraine. Erenumab was further investigated in the Phase 3b LIBERTY study of patients with migraine who had failed on 2-4 previous preventive therapies.

Download slideset »

« back to Slides

Educational Partners and Supporters

Lilly

This program is funded in part via an independent educational grant from AbbVie

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2024 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach |